시장보고서

상품코드

1553610

협심증약 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 약제 클래스별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Angina Pectoris Drugs Market Size, Share & Trends Analysis Report By Type (Stable Angina, Unstable Angina), By Drug Class (Beta Blockers, Anticoagulants), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 08월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

협심증약 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 협심증약 시장 규모는 2030년까지 157억 1,000만 달러에 달하며, 2024-2030년 CAGR은 4.0%를 기록할 것으로 예측됩니다.

세계 협심증 시장은 질병 변형 치료 및 표적 치료에 대한 수요, 의료비 지출 증가, 신흥 시장 전반에 걸친 효과적인 치료법의 가용성에 의해 주도되고 있습니다.

또한 협심증 유병률과 발생률 증가는 시장 성장을 가속할 것으로 예측됩니다. 만성 안정형 협심증 유병률은 미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본 등 신흥 국가 시장에서 2.0-4.0%에 달할 전망입니다. 협심증 유병률은 남녀 모두 연령에 따라 급격하게 증가하는데, 남성은 45-54세에서 2.0-5.0%, 65-74세에서 10.0-20.0%, 여성은 45-54세에서 0.1-1.0%, 65-74세에서 10.0-15.0%로 나타났습니다. 건강한 생활습관을 통해 질환의 증상을 관리할 수 있습니다.

협심증 치료제 시장의 하이라이트

협심증 치료제 시장은 안정형 협심증 분야가 2023년 매출 점유율 52.2%를 차지했습니다. 만성 안정형 협심증 환자 수가 증가하고 있으며, 그 중 절반 가까이가 허혈성 심장질환의 초기 증상으로 발병하고 있습니다.
2023년 협심증 시장은 베타차단제가 38.8%의 매출 점유율로 시장을 주도했습니다. 이 부문의 성장은 협심증 1차 선택 약물로 채택이 증가하고 있기 때문입니다.
2023년 협심증 치료제 시장은 병원 약국이 48.5%의 매출 점유율로 압도적인 점유율을 차지할 것으로 예상됩니다. 이는 첨단 인프라와 적절한 시설을 갖춘 병원이 협심증 치료를 위해 병원을 찾는 환자 수가 증가하고 있다는 사실에 기인합니다.
북미 협심증 치료제 시장은 2023년 40.0% 이상의 매출 점유율로 세계 협심증 치료제 시장을 장악했습니다. 저침습적 치료에 대한 수요 증가는 예측 기간 중 시장 성장을 촉진할 것으로 예상됩니다.
아시아태평양 협심증 치료제 시장은 CAGR 5.5%로 세계 협심증 치료제 시장에서 가장 빠르게 성장할 것으로 예상됩니다.

협심증약 시장 점유율, 지역별, 2023년 및 2030년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 구도

주요 시장 참여 기업에 의한 최근 동향과 영향 분석
기업 분류
기업 히트맵 분석
기업 개요
- Pfizer Inc.
- Bayer AG
- AstraZeneca
- Gilead Sciences
- Novartis AG
- GlaxoSmithKline Plc.
- Merck &Co., Inc.
- Amgen Inc.
- Eli Lilly and Company
- Otsuka Pharmaceutical Co., Ltd.
- Sanofi SA
- Boehringer Ingelheim International GmbH

KSA 24.09.25

Angina Pectoris Drugs Market Growth & Trends:

The global angina pectoris drugs market is expected to be valued at USD 15.71 billion by 2030, registering a CAGR of 4.0% from 2024 to 2030, as per a new report by Grand View Research, Inc. The global angina pectoris market is collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare and availability of effective treatment methods across the emerging markets.

Additionally, the rising prevalence and incidence of angina pectoris is anticipated to fuel the market growth. Chronic stable angina pectoris has a prevalence of 2.0-4.0% in developed markets such as the U.S., the U.K., Germany, France, Italy, Spain and Japan. The prevalence of angina pectoris rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74, and from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74. The disease symptoms can be managed by following a healthy lifestyle.

Angina Pectoris Drugs Market Report Highlights:

The stable angina segment dominated the angina pectoris drug market with a revenue share of 52.2% in 2023. The number of patients suffering from chronic stable angina is rising, and almost half of these patients have it as the initial sign of ischemic heart disease.
Beta blockers dominated the angina pectoris market in 2023 with a revenue share of 38.8%. Segment growth is primarily driven by its increasing adoption as a first-line therapy for angina pectoris.
Hospital pharmacies dominate the angina pectoris drugs market with a revenue share of 48.5% in 2023. This can be attributed to the fact that hospitals equipped with advanced infrastructure and suitable facilities are witnessing a rise in the number of patients seeking treatment for angina pectoris disorders.
North America angina pectoris drugs market dominated the global angina pectoris drugs market with a revenue share of over 40.0% in 2023. The increasing demand for minimally invasive procedures is expected to drive the market's growth in the forecast period.
Angina pectoris drugs market in Asia Pacific is expected the fastest growth in the global angina pectoris drugs market with a CAGR of 5.5%.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Angina Pectoris Drugs Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Angina Pectoris Drugs Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Angina Pectoris Drugs Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Angina Pectoris Drugs Market: Type Movement Analysis, 2023 & 2030 (USD Million)
4.3. Stable Angina
- 4.3.1. Stable Angina Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Unstable Angina
- 4.4.1. Unstable Angina Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Microvascular Angina
- 4.5.1. Microvascular Angina Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Prinzmetal Angina
- 4.6.1. Prinzmetal Angina Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Angina Pectoris Drugs Market: Drug Class Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Angina Pectoris Drugs Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
5.3. Beta Blockers
- 5.3.1. Beta Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Calcium Antagonists
- 5.4.1. Calcium Antagonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Nitrates
- 5.5.1. Nitrates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Anticoagulants
- 5.6.1. Anticoagulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Anti-Platelets
- 5.7.1. Anti-Platelets Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Other Drug Classes
- 5.8.1. Other Drug Classes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Angina Pectoris Drugs Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Angina Pectoris Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacy
- 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacy
- 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacy
- 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Angina Pectoris Drugs Market: Regional Estimates & Trend Analysis

7.1. Angina Pectoris Drugs Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
- 7.2.1. North America Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Italy Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Spain Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Norway Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Japan Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. China
  - 7.4.3.1. China Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. Australia
  - 7.4.5.1. Australia Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. South Korea
  - 7.4.6.1. South Korea Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Saudi Arabia Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. UAE
  - 7.6.4.1. UAE Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Angina Pectoris Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. Pfizer Inc.
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/Strategic Initiatives
- 8.4.2. Bayer AG
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/Strategic Initiatives
- 8.4.3. AstraZeneca
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/Strategic Initiatives
- 8.4.4. Gilead Sciences
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/Strategic Initiatives
- 8.4.5. Novartis AG
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/Strategic Initiatives
- 8.4.6. GlaxoSmithKline Plc.
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/Strategic Initiatives
- 8.4.7. Merck & Co., Inc.
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/Strategic Initiatives
- 8.4.8. Amgen Inc.
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/Strategic Initiatives
- 8.4.9. Eli Lilly and Company
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/Strategic Initiatives
- 8.4.10. Otsuka Pharmaceutical Co., Ltd.
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/Strategic Initiatives
- 8.4.11. Sanofi S.A.
  - 8.4.11.1. Participant's Overview
  - 8.4.11.2. Financial Performance
  - 8.4.11.3. Product Benchmarking
  - 8.4.11.4. Recent Developments/Strategic Initiatives
- 8.4.12. Boehringer Ingelheim International GmbH
  - 8.4.12.1. Participant's Overview
  - 8.4.12.2. Financial Performance
  - 8.4.12.3. Product Benchmarking
  - 8.4.12.4. Recent Developments/Strategic Initiatives

협심증약 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 약제 클래스별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Angina Pectoris Drugs Market Size, Share & Trends Analysis Report By Type (Stable Angina, Unstable Angina), By Drug Class (Beta Blockers, Anticoagulants), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

협심증약 시장의 성장과 동향 :

협심증 치료제 시장의 하이라이트

목차

제1장 조사 방법과 범위

제2장 개요

제3장 협심증약 시장의 변수, 동향, 범위

제4장 협심증약시장 : 유형별 추정·동향 분석

제5장 협심증약시장 : 약제 클래스별 추정·동향 분석

제6장 협심증약시장 : 유통 채널별 추정·동향 분석

제7장 협심증약시장 : 지역별 추정·동향 분석